RGEN Key Statistics, Chart & Performance
The current stock price of RGEN is 162.51 USD. In the past month the price decreased by -2.3%. In the past year, price increased by 13.98%.
RGEN Latest News, Press Relases and Analysis
RGEN Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| TMO | THERMO FISHER SCIENTIFIC INC | 26.23 | 221.84B | ||
| DHR | DANAHER CORP | 29.49 | 162.82B | ||
| BRKRP | BRUKER CORP - BRKR 6 3/8 09/01/28 | 182.53 | 55.39B | ||
| A | AGILENT TECHNOLOGIES INC | 27.75 | 42.88B | ||
| IQV | IQVIA HOLDINGS INC | 19.34 | 38.23B | ||
| MTD | METTLER-TOLEDO INTERNATIONAL | 34.71 | 29.92B | ||
| WAT | WATERS CORP | 31.02 | 23.45B | ||
| WST | WEST PHARMACEUTICAL SERVICES | 38.34 | 19.49B | ||
| ILMN | ILLUMINA INC | 28.41 | 19.04B | ||
| MEDP | MEDPACE HOLDINGS INC | 41.39 | 16.62B | ||
| TEM | TEMPUS AI INC | N/A | 12.21B | ||
| RVTY | REVVITY INC | 20.52 | 11.41B |
Related stock screener links
About RGEN
Company Profile
Repligen Corp. is a global life sciences company, which engages in providing bioprocessing technologies and solutions used in the process of manufacturing biological drugs. The company is headquartered in Waltham, Massachusetts and currently employs 1,778 full-time employees. Its focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Its filtration products are used in process development and process scale (clinical and commercial) production. Its XCell ATF systems are used in upstream perfusion (continuous) and N-1 (intensified fed-batch or hybrid perfusion) cell culture processing. Its chromatography franchise includes several products used in downstream purification, development, manufacturing and quality control of biological drugs. Its process analytics products complement and support its filtration, chromatography and protein franchises. Its TangenX product portfolio includes flat sheet (FS) tangential flow filtration (TFF) cassettes used primarily in downstream and ultrafiltration processes. Its desktop portfolio includes MAVERICK and MAVEN, REBEL, and ZipChip.
Company Info
REPLIGEN CORP
Building 1, Suite 100, 41 Seyon Street
Waltham MASSACHUSETTS 02453 US
CEO: Tony J. Hunt
Employees: 1778
Phone: 17814499560
REPLIGEN CORP / RGEN FAQ
Can you describe the business of REPLIGEN CORP?
Repligen Corp. is a global life sciences company, which engages in providing bioprocessing technologies and solutions used in the process of manufacturing biological drugs. The company is headquartered in Waltham, Massachusetts and currently employs 1,778 full-time employees. Its focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Its filtration products are used in process development and process scale (clinical and commercial) production. Its XCell ATF systems are used in upstream perfusion (continuous) and N-1 (intensified fed-batch or hybrid perfusion) cell culture processing. Its chromatography franchise includes several products used in downstream purification, development, manufacturing and quality control of biological drugs. Its process analytics products complement and support its filtration, chromatography and protein franchises. Its TangenX product portfolio includes flat sheet (FS) tangential flow filtration (TFF) cassettes used primarily in downstream and ultrafiltration processes. Its desktop portfolio includes MAVERICK and MAVEN, REBEL, and ZipChip.
What is the stock price of REPLIGEN CORP today?
The current stock price of RGEN is 162.51 USD. The price increased by 5.28% in the last trading session.
Does RGEN stock pay dividends?
RGEN does not pay a dividend.
What is the ChartMill rating of REPLIGEN CORP stock?
RGEN has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
Where is REPLIGEN CORP (RGEN) stock traded?
RGEN stock is listed on the Nasdaq exchange.
When does REPLIGEN CORP (RGEN) report earnings?
REPLIGEN CORP (RGEN) will report earnings on 2026-02-18, after the market close.
RGEN Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to RGEN. When comparing the yearly performance of all stocks, RGEN is one of the better performing stocks in the market, outperforming 88.07% of all stocks.
RGEN Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to RGEN. While RGEN has a great health rating, its profitability is only average at the moment.
RGEN Financial Highlights
Over the last trailing twelve months RGEN reported a non-GAAP Earnings per Share(EPS) of 1.66. The EPS increased by 21.17% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 0.25% | ||
| ROA | 0.06% | ||
| ROE | 0.08% | ||
| Debt/Equity | 0.26 |
RGEN Forecast & Estimates
28 analysts have analysed RGEN and the average price target is 191.18 USD. This implies a price increase of 17.64% is expected in the next year compared to the current price of 162.51.
For the next year, analysts expect an EPS growth of 15.05% and a revenue growth 15.25% for RGEN